Total Payments
$285.01
2024 Payments
$31.93
Companies
4
Transactions
15
Medicare Patients
493
Medicare Billing
$432,293
Payment Breakdown by Category
Food & Beverage$266.36 (93.5%)
Education$18.65 (6.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $266.36 | 14 | 93.5% |
| Education | $18.65 | 1 | 6.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Indivior Inc. | $129.38 | 7 | $0 (2024) |
| Orexo US, Inc. | $93.99 | 5 | $0 (2023) |
| Gilead Sciences, Inc. | $38.83 | 2 | $0 (2019) |
| Alkermes, Inc. | $22.81 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $31.93 | 2 | Indivior Inc. ($31.93) |
| 2023 | $61.09 | 3 | Alkermes, Inc. ($22.81) |
| 2022 | $16.10 | 1 | Orexo US, Inc. ($16.10) |
| 2021 | $55.90 | 2 | Orexo US, Inc. ($33.50) |
| 2019 | $119.99 | 7 | Indivior Inc. ($54.99) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/01/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: OUD | ||||||
| 05/20/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $14.06 | General |
| Category: OUD | ||||||
| 05/02/2023 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $18.22 | General |
| Category: Addiction Medicine | ||||||
| 04/11/2023 | Alkermes, Inc. | Vivitrol (Drug) | Food and Beverage | In-kind items and services | $22.81 | General |
| Category: CNS | ||||||
| 03/07/2023 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: OUD | ||||||
| 01/06/2022 | Orexo US, Inc. | — | Food and Beverage | Cash or cash equivalent | $16.10 | General |
| 12/21/2021 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: OUD | ||||||
| 11/11/2021 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $33.50 | General |
| Category: Addiction Medicine | ||||||
| 09/27/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.47 | General |
| 07/25/2019 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $12.65 | General |
| Category: Addiction Medicine | ||||||
| 06/27/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.36 | General |
| 06/06/2019 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $21.55 | General |
| Category: OUD | ||||||
| 06/06/2019 | Indivior Inc. | SUBLOCADE (Drug) | Education | In-kind items and services | $18.65 | General |
| Category: OUD | ||||||
| 04/24/2019 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $13.52 | General |
| Category: Addiction Medicine | ||||||
| 03/14/2019 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: OUD | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 101 | 647 | $132,310 | $55,227 |
| 2022 | 6 | 128 | 1,103 | $220,710 | $100,121 |
| 2021 | 5 | 105 | 1,194 | $217,250 | $112,493 |
| 2020 | 5 | 159 | 2,002 | $307,931 | $164,451 |
Total Patients
493
Total Services
4,946
Medicare Billing
$432,293
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 25 | 180 | $32,400 | $20,185 | 62.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 20 | 149 | $46,190 | $15,472 | 33.5% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 28 | 221 | $33,150 | $13,459 | 40.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 14 | 74 | $18,500 | $5,662 | 30.6% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 14 | 23 | $2,070 | $449.98 | 21.7% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 29 | 250 | $45,000 | $28,248 | 62.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 21 | 215 | $66,650 | $23,337 | 35.0% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2022 | 34 | 370 | $55,500 | $22,713 | 40.9% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 11 | 108 | $22,680 | $16,710 | 73.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 103 | $25,750 | $7,910 | 30.7% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 17 | 57 | $5,130 | $1,202 | 23.4% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 24 | 298 | $50,560 | $34,100 | 67.4% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2021 | 27 | 416 | $62,400 | $25,850 | 41.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 20 | 167 | $49,790 | $19,354 | 38.9% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 12 | 115 | $21,900 | $18,008 | 82.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 22 | 198 | $32,600 | $15,181 | 46.6% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2020 | 37 | 445 | $71,200 | $50,505 | 70.9% |
| 80307 | Testing for presence of drug | Office | 2020 | 42 | 676 | $101,400 | $41,679 | 41.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 40 | 591 | $88,650 | $36,757 | 41.5% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2020 | 17 | 221 | $39,781 | $34,359 | 86.4% |
| 99211 | Established patient office or other outpatient visit, typically 5 minutes | Office | 2020 | 23 | 69 | $6,900 | $1,151 | 16.7% |
About Melvin Nemkov
Melvin Nemkov is a Internal Medicine healthcare provider based in Chelmsford, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/24/2007. The National Provider Identifier (NPI) number assigned to this provider is 1649325283.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Melvin Nemkov has received a total of $285.01 in payments from pharmaceutical and medical device companies, with $31.93 received in 2024. These payments were reported across 15 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($266.36).
As a Medicare-enrolled provider, Nemkov has provided services to 493 Medicare beneficiaries, totaling 4,946 services with total Medicare billing of $432,293. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Chelmsford, MA
- Active Since 01/24/2007
- Last Updated 07/28/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1649325283
Products in Payments
- SUBLOCADE (Drug) $129.38
- Zubsolv (Drug) $77.89
- Vivitrol (Drug) $22.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Chelmsford
Ami Mehra, M.d, M.D
Internal Medicine — Payments: $62,110
Internal Medicine $62,110
Ankit Patel, M.d, M.D
Internal Medicine — Payments: $17,657
Internal Medicine $17,657
Jonathan Harding, M.d, M.D
Internal Medicine — Payments: $4,502
Internal Medicine $4,502
Dr. Richard Deamicis, M.d, M.D
Internal Medicine — Payments: $4,253
Internal Medicine $4,253
Manoj Moholkar, M.d, M.D
Internal Medicine — Payments: $2,850
Internal Medicine $2,850
Dr. Janarthanan Someswarananthan, Md, MD
Internal Medicine — Payments: $704.04
Internal Medicine $704.04